

LPA1 antagonist AMS-III-1086; Pre-clinical study for liver fibrosis treatment

AM Sciences Co., Ltd.



METABOLIC	Non-clinical
Product Type	Small Molecule
Indication	Liver Fibrosis (NASH)
Target	LPAR1
MoA(Mechanism of Action)	LPAR1 Antagonist
Competitiveness	<ul style="list-style-type: none"> • High selectivity to LPAR1 • Improved bioactivity (Ca²⁺flux assay EC₅₀ = 6.8 nM, Chemotaxis assay EC₅₀ = 19.7 nM) • Reduced drug-induced liver injury (DILI) liability • Expansion of indications for fibrosis induced in various organs
Development Stage	Non-clinical
Route of Administration	Oral administration